GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (OTCPK:GNHAF) » Definitions » EV-to-EBITDA

Vifor Pharma AG (Vifor Pharma AG) EV-to-EBITDA : 16.03 (As of May. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Vifor Pharma AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vifor Pharma AG's enterprise value is $11,232 Mil. Vifor Pharma AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 was $701 Mil. Therefore, Vifor Pharma AG's EV-to-EBITDA for today is 16.03.

The historical rank and industry rank for Vifor Pharma AG's EV-to-EBITDA or its related term are showing as below:

GNHAF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.61   Med: 19.46   Max: 30.22
Current: 17.15

During the past 13 years, the highest EV-to-EBITDA of Vifor Pharma AG was 30.22. The lowest was 12.61. And the median was 19.46.

GNHAF's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 14.53 vs GNHAF: 17.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Vifor Pharma AG's stock price is $181.25. Vifor Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $2.441. Therefore, Vifor Pharma AG's PE Ratio for today is 74.25.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Vifor Pharma AG EV-to-EBITDA Historical Data

The historical data trend for Vifor Pharma AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG EV-to-EBITDA Chart

Vifor Pharma AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.71 18.91 21.95 17.06 16.34

Vifor Pharma AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.95 - 17.06 - 16.34

Competitive Comparison of Vifor Pharma AG's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vifor Pharma AG's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's EV-to-EBITDA falls into.



Vifor Pharma AG EV-to-EBITDA Calculation

Vifor Pharma AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=11231.729/700.616
=16.03

Vifor Pharma AG's current Enterprise Value is $11,232 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vifor Pharma AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 was $701 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vifor Pharma AG  (OTCPK:GNHAF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vifor Pharma AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=181.25/2.441
=74.25

Vifor Pharma AG's share price for today is $181.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vifor Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $2.441.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Vifor Pharma AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vifor Pharma AG (Vifor Pharma AG) Business Description

Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (Vifor Pharma AG) Headlines